Aspirin in Primary Prevention: Is There Still a Role?

What Do Current Guidelines Say?

ACC/AHA

The ACC/AHA guideline states that low-dose aspirin 75–100 mg daily may be considered selectively in adults approximately 40–70 years old who have higher ASCVD risk but are not at increased bleeding risk.

Routine aspirin is discouraged in adults over 70 and in people with increased bleeding risk.

Practical interpretation

High cardiovascular risk + low bleeding risk + appropriate age

may justify a discussion about aspirin.

It does not mean that aspirin should automatically be prescribed.

The U.S. Preventive Services Task Force (USPSTF) Recommendation

The USPSTF takes a similarly selective approach.

Age 40–59 years

For individuals with:

≥10% estimated 10-year CVD risk

the decision to initiate low-dose aspirin should be individualized because the net benefit is small.

Age ≥60 years

The USPSTF recommends:

Do not initiate aspirin routinely for primary prevention.

Importantly, this recommendation concerns starting aspirin for primary prevention. It should not be interpreted as meaning that every patient already taking aspirin should abruptly stop it without discussing the indication with their clinician.

What About Diabetes?

This is one of the most common clinical questions.

Does diabetes automatically mean aspirin?

No.

The ASCEND trial showed that aspirin reduced serious vascular events in patients with diabetes without established cardiovascular disease, but major bleeding increased substantially as well.

Therefore:

Diabetes increases cardiovascular risk, but diabetes alone is not sufficient justification for aspirin.

Aspirin may occasionally be considered when cardiovascular risk is particularly high and bleeding risk is low.

Who Might Still Be Considered for Aspirin?

A carefully selected patient may be considered when most of the following are present:

Cardiovascular risk

• High estimated ASCVD/CVD risk
• Multiple major cardiovascular risk factors
• Particularly high overall atherosclerotic risk

Bleeding risk

• No previous major gastrointestinal bleeding
• No active peptic ulcer disease
• No previous intracranial hemorrhage
• No significant bleeding disorder
• No major thrombocytopenia
• No major medication-related bleeding risk

Patient factors

• Generally younger than 70 years
• Understands that the cardiovascular benefit is modest
• Accepts the potential bleeding risk
• Participates in shared decision-making

Who Should Generally Avoid Aspirin for Primary Prevention?

Factors arguing against aspirin include:

• Previous gastrointestinal bleeding
• Peptic ulcer disease
• Previous intracranial hemorrhage
• Anticoagulant therapy
• Thrombocytopenia
• Chronic kidney disease
• Uncontrolled hypertension
• Regular NSAID use
• Advanced age
• Other conditions associated with increased bleeding risk

These factors are important because cardiovascular risk and bleeding risk do not necessarily rise together.

The Most Important Clinical Principle

Before considering aspirin, clinicians should optimize interventions with a much better benefit-to-risk ratio.

The prevention hierarchy

1. Stop smoking

↓

2. Control blood pressure

↓

3. Optimize LDL cholesterol

↓

4. Treat diabetes appropriately

↓

5. Exercise regularly

↓

6. Optimize weight and metabolic health

↓

7. Assess overall cardiovascular risk

↓

8. Assess bleeding risk

↓

9. Consider aspirin only in carefully selected patients

This approach is more important than simply asking:

“Should I take aspirin?”

The better question is:

“What is my absolute cardiovascular risk, what is my bleeding risk, and does aspirin provide enough additional benefit to justify that bleeding risk?”

Aspirin and CAC Score: Does Coronary Calcium Change the Decision?

A high coronary artery calcium (CAC) score indicates a higher burden of coronary atherosclerosis and may identify people whose cardiovascular risk is underestimated by conventional risk calculators.

Therefore, CAC can sometimes help with risk refinement.

However:

A high CAC score does not automatically mean “take aspirin.”

The decision still requires assessment of:

• Absolute ASCVD risk
• CAC burden
• Age
• Bleeding risk
• Other preventive therapies
• Patient preferences

In other words:

CAC may help identify a patient with higher potential cardiovascular benefit—but it does not eliminate aspirin’s bleeding risk.

This is particularly important because aspirin should not become a reflex response to an abnormal CAC score.

A Practical 2026 Aspirin Decision Algorithm

STEP 1 — Does the patient have established ASCVD?

YES → aspirin may be indicated for secondary prevention, depending on the clinical situation.

NO → proceed to primary-prevention assessment.

STEP 2 — Estimate cardiovascular risk

Assess:

• Age
• Blood pressure
• Lipids
• Diabetes
• Smoking
• Family history
• Other risk-enhancing factors
• Evidence of subclinical atherosclerosis when appropriate

STEP 3 — Assess bleeding risk

Ask about:

• Previous GI bleeding
• Peptic ulcer disease
• Intracranial bleeding
• Anticoagulants
• NSAIDs
• Kidney disease
• Thrombocytopenia
• Uncontrolled hypertension
• Advanced age

STEP 4 — Optimize conventional prevention first

Statin therapy, blood-pressure control, smoking cessation, diabetes management, exercise and weight optimization generally provide a more favorable preventive strategy.

STEP 5 — Shared decision-making

Only when cardiovascular risk is sufficiently high and bleeding risk is sufficiently low should aspirin be discussed.

STEP 6 — Reassess periodically

Aspirin is not a “set it and forget it” medication in primary prevention.

Risk changes with:

• Age
• New diseases
• New medications
• Bleeding episodes
• Changes in cardiovascular risk

Aspirin Primary Prevention: The Bottom Line

Should everyone take a baby aspirin?

No.

Should people with diabetes automatically take aspirin?

No.

Should people over 60 start aspirin routinely for primary prevention?

No.

Can aspirin still have a role?

Yes—but only selectively.

The contemporary evidence shows that aspirin can reduce first cardiovascular events, but the absolute benefit is modest and is frequently offset by major bleeding.

Therefore:

Aspirin in primary prevention should be the exception—not the rule.

For most people without established ASCVD, the priority should be aggressive management of modifiable cardiovascular risk factors rather than routine aspirin therapy.

Frequently Asked Questions

1. Is aspirin still useful for heart attack prevention?

Yes, but the answer depends on whether prevention is primary or secondary.

Aspirin remains an important treatment in many patients with established ASCVD. Its routine use in people who have never had cardiovascular disease is much less favorable.

2. Should a healthy 65-year-old start aspirin?

Generally, aspirin should not be routinely initiated for primary prevention at this age. The USPSTF recommends against initiating aspirin for primary prevention in adults aged 60 years or older.

3. I have diabetes. Should I take aspirin?

Not automatically. ASCEND demonstrated a reduction in serious vascular events but a similar-sized increase in major bleeding.

4. Does a high cholesterol level mean I need aspirin?

No. The first priority is appropriate lipid-lowering therapy and comprehensive cardiovascular-risk reduction.

5. Does a high CAC score mean I should take aspirin?

Not automatically. CAC can help refine cardiovascular risk, but aspirin still requires an assessment of bleeding risk and expected absolute benefit.

6. Can I stop aspirin if I have been taking it for years?

Do not stop prescribed aspirin without discussing it with your doctor.

The reason for aspirin matters. Aspirin prescribed after a heart attack, coronary stent, stroke, or established ASCVD is a different situation from aspirin started solely for primary prevention.

7. Is low-dose aspirin completely safe?

No.

Even low-dose aspirin can cause major gastrointestinal or intracranial bleeding.

Key Take-Home Messages

1. Aspirin remains important for many patients with established cardiovascular disease.

2. Routine aspirin is no longer recommended for most people without established ASCVD.

3. The cardiovascular benefit in primary prevention is modest.

4. Major bleeding is the principal trade-off.

5. Diabetes alone is not an indication for aspirin.

6. Older age does not automatically justify aspirin—in fact, bleeding risk becomes increasingly important.

7. Cardiovascular risk and bleeding risk must be assessed together.

8. Smoking cessation, blood-pressure control, LDL reduction, diabetes management, exercise and weight optimization should come first.

9. Aspirin may still be reasonable in a carefully selected high-risk patient with low bleeding risk.

10. Primary prevention with aspirin should be an individualized shared decision—not a routine prescription.

One-Line Clinical Summary

In 2026, aspirin for primary cardiovascular prevention is best viewed as a selective risk–benefit decision rather than a routine preventive medication.